1. Home
  2. SLN vs TG Comparison

SLN vs TG Comparison

Compare SLN & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • TG
  • Stock Information
  • Founded
  • SLN 1994
  • TG 1988
  • Country
  • SLN United Kingdom
  • TG United States
  • Employees
  • SLN N/A
  • TG N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • TG Metal Fabrications
  • Sector
  • SLN Health Care
  • TG Industrials
  • Exchange
  • SLN Nasdaq
  • TG Nasdaq
  • Market Cap
  • SLN 273.9M
  • TG 301.0M
  • IPO Year
  • SLN N/A
  • TG 1989
  • Fundamental
  • Price
  • SLN $6.11
  • TG $8.82
  • Analyst Decision
  • SLN Buy
  • TG
  • Analyst Count
  • SLN 5
  • TG 0
  • Target Price
  • SLN $32.60
  • TG N/A
  • AVG Volume (30 Days)
  • SLN 105.4K
  • TG 80.8K
  • Earning Date
  • SLN 08-14-2025
  • TG 08-06-2025
  • Dividend Yield
  • SLN N/A
  • TG N/A
  • EPS Growth
  • SLN N/A
  • TG N/A
  • EPS
  • SLN N/A
  • TG N/A
  • Revenue
  • SLN $27,701,000.00
  • TG $617,839,000.00
  • Revenue This Year
  • SLN N/A
  • TG N/A
  • Revenue Next Year
  • SLN N/A
  • TG N/A
  • P/E Ratio
  • SLN N/A
  • TG N/A
  • Revenue Growth
  • SLN N/A
  • TG 17.42
  • 52 Week Low
  • SLN $1.97
  • TG $4.87
  • 52 Week High
  • SLN $22.47
  • TG $9.43
  • Technical
  • Relative Strength Index (RSI)
  • SLN 55.70
  • TG 57.26
  • Support Level
  • SLN $6.10
  • TG $8.82
  • Resistance Level
  • SLN $6.67
  • TG $9.11
  • Average True Range (ATR)
  • SLN 0.39
  • TG 0.24
  • MACD
  • SLN -0.02
  • TG -0.02
  • Stochastic Oscillator
  • SLN 59.70
  • TG 53.95

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: